A Phase I Open label, Dose Finding Study of IMCgp100 in Patients with Advanced Malignant Melanoma

Conditions

Melanoma, skin

What is the purpose of this trial?

This is a Phase 1, open-label, dosefinding study to assess the safety and tolerability of IMCgp100, a Monoclonal T Cell Receptor anti-CD3 scFv Fusion Protein, in patients with advanced malignant melanoma. Eligible patients will have Stage IV disease or unresectable Stage III disease.


Participation Guidelines

Age:
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Immunocore
Dates:
07/23/2013
Last Updated:
Study HIC#:
1302011504